Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...

Expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, according to a new report from the ...

Semaglutide vs liraglutide treatment demonstrated superior weight loss at 1 year and 10% weight loss achievement among patients with obesity.

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...

The benefits do not stop there. Recent studies suggest GLP-1 drugs may also reduce the risk of heart disease, kidney disease and stroke, and even possibly protect the brain from AD by reducing ...

Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs.

Kailera Therapeutics launched on Tuesday as the latest startup seeking a slice of the booming market for anti-obesity therapies with a rare $400 million in early-stage funding.

Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but ...

It’s the main calculation used to assess healthy body weight and helps determine eligibility for in-demand GLP-1 weight-loss drugs. It’s also imprecise at best, misleading at worst, ...

approved by the US Food and Drug Administration in 2010 for type 2 diabetes. In the meantime, researchers were already exploring the drugs’ weight-loss potential, and in 2014, liraglutide became ...

The underlying message? They “just need to lose weight” to fix almost any health problem. Society’s focus on weight has shaped how most Australians view health and body weight, often pushing ...